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Minocycline as a re-purposed 
anti-Wolbachia macrofilaricide: 
superiority compared with 
doxycycline regimens in a murine 
infection model of human 
lymphatic filariasis
Raman Sharma, Ghaith Al Jayoussi, Hayley E. Tyrer, Joanne Gamble, Laura Hayward, 
Ana F. Guimaraes, Jill Davies, David Waterhouse, Darren A. N. Cook, Laura J. Myhill, 
Rachel H. Clare, Andrew Cassidy, Andrew Steven, Kelly L. Johnston, Louise Ford, 
Joseph D. Turner, Stephen A. Ward & Mark J. Taylor
Lymphatic filariasis and onchocerciasis are parasitic helminth diseases, which cause severe morbidities 
such as elephantiasis, skin disease and blindness, presenting a major public health burden in endemic 
communities. The anti-Wolbachia consortium (A·WOL: http://www.a-wol.com/) has identified a 
number of registered antibiotics that target the endosymbiotic bacterium, Wolbachia, delivering 
macrofilaricidal activity. Here we use pharmacokinetics/pharmacodynamics (PK/PD) analysis to 
rationally develop an anti-Wolbachia chemotherapy by linking drug exposure to pharmacological 
effect. We compare the pharmacokinetics and anti-Wolbachia efficacy in a murine Brugia malayi model 
of minocycline versus doxycycline. Doxycycline exhibits superior PK in comparison to minocycline 
resulting in a 3-fold greater exposure in SCID mice. Monte-Carlo simulations confirmed that a bi-daily  
25–40 mg/Kg regimen is bioequivalent to a clinically effective 100–200 mg/day dose for these 
tetracyclines. Pharmacodynamic studies showed that minocycline depletes Wolbachia more effectively 
than doxycycline (99.51% vs. 90.35%) after 28 day 25 mg/Kg bid regimens with a more potent block 
in microfilarial production. PK/PD analysis predicts that minocycline would be expected to be 1.7 fold 
more effective than doxycycline in man despite lower exposure in our infection models. Our findings 
warrant onward clinical investigations to examine the clinical efficacy of minocycline treatment 
regimens against lymphatic filariasis and onchocerciasis.
Lymphatic filariasis (LF) and onchocerciasis are parasitic helminth diseases affecting an estimated 158 million 
people globally, causing a substantial socioeconomic and health burden in endemic communities1–3. Lymphatic 
filariasis, caused by the filarial nematodes Wuchereria bancrofti, Brugia malayi and B. timori affects an esti-
mated 120 million people. Morbidity associated with LF includes lymphoedema, elephantiasis and hydrocele1,3. 
Onchocerciasis is caused by Onchocerca volvulus and affects approximately 38 million people. Symptomatically, 
onchocerciasis presents as skin disease and can cause loss of sight in advanced untreated cases due to the immune 
response to migration and death of microfilariae in the eye2,3.
Current filariasis treatment and control programs rely on the use of the microfilaricides diethylcarbamazine, 
ivermectin, and albendazole. In the context of mass drug administration (MDA), a combination of ivermectin and 
albendazole is used to control LF in Africa whereas a diethylcarbamazine/albendazole combination treatment is 
mainly used in the rest of the world3. In the case of onchocerciasis, ivermectin is administered as a monotherapy 
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during MDA in all endemic areas. Targeting the microfilariae has proved effective in many cases, however, the 
length of treatment required (5 years for LF and up to 17 years or more for onchocerciasis) combined with long 
life span of an adult worm means that transmission will not be interrupted in some cases, especially where MDA 
is disrupted3,4. Treatment in geographical regions in which Loa loa is co-endemic is further complicated as iver-
mectin can cause severe adverse reaction events (SAEs), which can result in encephalophathy, coma and death5. 
These SAEs are probably caused by the drug-induced paralysis and death of the Loa loa microfilariae in the brain6. 
There is also increasing evidence of ivermectin resistance emerging in some endemic regions7. Epidemiological 
modelling also suggests MDA based on a microfilaricide mode of action may not be effective for elimination in 
all scenarios8,9, therefore alternative treatment strategies that include the use of macrofilaricidal (curative) drugs 
require development to facilitate the elimination of filarial diseases10.
Lymphatic filariae and O. volvulus are host to the obligate endosymbiotic bacterium, Wolbachia, which is 
essential for their development, growth and survival10. Wolbachia also contribute to filarial disease pathology11,12 
and are associated with inflammatory adverse reactions to standard microfilaricidal treatments13,14. It has been 
shown that targeting Wolbachia with antibiotic drugs can induce growth retardation, embryotoxicity and death 
of adult filarial nematodes in preclinical models15,16 and in humans17. Doxycycline is the current gold standard 
anti-Wolbachia treatment with a growing body of clinical evidence that it has macrofilaricidal activity against 
LF18,19 and onchocerciasis20–22. Tetracyclines including doxycycline have been shown to suppress immune activ-
ity and therefore may offer the added benefit of alleviating symptomology23,24. This effect has been confirmed in 
clinical studies in which 200 mg/day doxycycline has been given for six weeks, showing reduced lymphangiogenic 
factors and filarial lymphedema25,26. Additionally, doxycycline is safe to use in Loa loa co-endemic areas as these 
parasites do not harbour Wolbachia22. The use of doxycycline in mass drug administration is however hampered 
by the duration of an optimally effective treatment (for onchocerciasis, recently defined as a minimum of 4 weeks, 
100 mg, in a meta-analytical modelling framework) which could pose a hurdle to treatment adherence27.
The anti-Wolbachia consortium (A·WOL) program has identified a number of registered antibiotics that 
were effective against Wolbachia in in vitro and in vivo model systems28. The tetracycline, minocycline, caused 
a 1.6-fold log drop in Wolbachia in an in vitro C6/36 (wAlbB) cell based screen when administered at a concen-
tration of 10 μM. A regimen of 25 mg/Kg/day of minocycline administered for 10 days elicited a log drop of 3.78 
in Wolbachia ftsZ DNA in the Litomosoides sigmodontis murine filariasis model28. The data suggest superiority 
of minocycline over doxycycline. In this current work, we have investigated and compared the anti-Wolbachia 
efficacy of orally administered minocycline and doxycycline against the human filarial parasite B. malayi in a 
SCID mouse model29. Using quantitative assessment of Wolbachia load and PK/PD analysis we show that for 
a dosage that is equivalent to a previous clinically effective 100–200 mg/day doxycycline dose, minocycline is 
significantly more efficacious. The origin of these efficacy differences has been dissected through analysis of the 
relative contributions of drug pharmacokinetics and pharmacodynamics. Treatment duration and dosage have 
been investigated to identify optimal treatment regimens.
Results
In vitro anti-Wolbachia potency of minocycline vs doxycycline. The anti-Wolbachia potency of min-
ocycline and doxycycline in in vitro Wolbachia infected A. albopictus cells C6/36 and in vitro male Brugia malayi 
worms harvested from untreated infected mice, is shown in Table 1. The data indicate that in vitro activities over-
lap for doxycycline and minocycline suggesting that both intrinsic antibiotic potency (in vitro data) and penetra-
tion of the filarial cuticle (in vitro worm data) are within the same range for both doxycycline and minocycline.
Pharmacokinetics of doxycycline and minocycline in BALB/c SCID mice. The pharmacokinet-
ics of doxycycline and minocycline were determined for a 7 day 25 mg/Kg qd chronic dosing regimen (equiva-
lent to the treatment regimens used in the murine infection studies). Table 2 shows the fitted pharmacokinetic 
Doxycycline Minocycline
In vitro depletion (insect Wolbachia) 
EC50, (range, n)
15.3 nM (1–147, 396) 11.8 nM (8–34, 6)
In vitro depletion (male B. malayi) 
@5 μM Median% depletion cf 
vehicle, (range, n)
65% (14–80%, 10) 66.7% (43–71%, 10)
Table 1.  In vitro anti-Wolbachia activities of doxycycline and minocycline in infected A. albopictus cells 
C6/36 and male Brugia malayi worms.
Doxycycline Minocycline
CL/F (L/hr/Kg) 1.2 (0.4) 3.2 (0.3)
V/F (L/Kg) 6.9 (3.9) 13.2 (4.5)
Half-life 4.4 (3.7) 3.0 (2.3)
AUC (mg.hr/L)0–24hr after dose 22.8 8.4
Table 2. Pharmacokinetic parameters for doxycycline and minocycline at steady state (day 7). Standard deviations 
are show in parentheses.
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profiles at steady state (day 7) for doxycycline and minocycline. Pharmacokinetic parameters for doxycycline 
day 1 were found to be not statistically different to those determined at steady state (Mann-Whitney test, n = 5, 
P-value > 0.05), this is consistent with there being no reports of time-dependent kinetics for tetracyclines in the 
literature. Figure 1 shows the predicted population PK profiles for doxycycline and minocycline. Minocycline was 
found to have a larger apparent clearance (CL/F: 3.2 vs. 1.2 L/h/Kg) and higher apparent volume of distribution 
than doxycycline (V/F: 13.2 vs. 6.9 L/hr). The elimination half-lives determined in BALB/c SCID mice were found 
to be comparable with those reported in the literature for doxycycline and minocycline in mice30,41. From Table 2 
it can be seen that these differences lead to minocycline having approximately 3-fold less systemic exposure than 
doxycycline.
Calculating murine dosage regimens bioequivalent to clinically relevant exposures. Monte Carlo 
simulations were used to calculate murine dosage regimens that give bioequivalent exposures to standard clinical 
100–200 mg/day doses of second-generation tetracyclines. The distributions of human exposures of doxycycline 
and minocycline were based on pharmacokinetic parameters from the literature31,32. Figure 2 shows the simulated 
human pharmacokinetic profiles of 200 mg doses of doxycycline and minocycline overlaid with their respective 
bioequivalent murine pharmacokinetic profiles given as either once-daily or twice daily regimens. From sim-
ulation it has been determined that a 25 mg/Kg bid dosage regimen closely emulates overall daily exposure of 
a 100–200 mg clinical dose for both tetracyclines. For doxycycline oral doses of 100 mg and 200 mg in humans 
give mean exposures of 28.4 and 56.9 μg.hr/mL, whereas in mice 25 mg/Kg doses once or twice daily give mean 
exposures of 22.8 and 40.6 μg.hr/mL, respectively. For minocycline, 100 mg and 200 mg doses in the clinical yield 
exposures of 17.7 and 35.4 μg.hr/mL, whereas in mice 25 mg/Kg doses administered once or twice daily give 
exposures of 7.8 and 14.9 μg.hr/mL, respectively. Multiple daily doses are more preferable to higher dose once 
daily as this results in peak plasma concentrations that are more consistent with those most often achieved clin-
ically with a standard doses of tetracycline and the length of exposure is more reflective of the clinical plasma 
concentration-time profile.
Figure 1. Pharmacokinetic profiles for doxycycline and minocycline at day 7. Solid black line represents 
the median for a population of 1000 simulated individuals and the blue dashed lines depict the 5th and 95th 
percentile values for the population. Observed discreet concentrations are shown as grey circles.
Figure 2. Concentration-time profiles for human and murine pharmacokinetic studies. Median human 
pharmacokinetic profile (200 mg dose) is shown as a solid black line and the blue dashed lines depict the 5th 
and 95th percentile values for a population simulated population of 1000 individuals. Median 25 mg/Kg bid and 
50 mg/Kg murine pharmacokinetic profiles are show in green and red solid lines, respectively.
www.nature.com/scientificreports/
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Comparative in vivo efficacy of clinical bioequivalent doxycycline and minocycline regimens 
against adult stage Brugia malayi Wolbachia. To directly compare efficacy of minocycline against dox-
ycycline, dosages determined bioequivalent to typical human exposures; 25 mg/Kg either once or twice daily, 
were orally administered to B. malayi-infected SCID mice (Fig. 3a). Dose durations were extended up to 42 days, 
to match proven macrofilaricidal 4–6 week doxycycline clinical dosage regimens (defined as depletion of >90% 
Wolbachia from nematode tissues)14,33.
Table 3 details the adult parasitological outcomes post-doxycycline or minocycline treatment. Approximately 
90% (19/22) of vehicle control treated SCID mice harboured fecund, motile B. malayi at +12 weeks (median 
6 worms/animal, range 0–19, sex ratio 59.2% female). As predicted for slow-acting macrofilaricides targeting 
Wolbachia, neither doxycycline nor minocycline, at any regimen tested, exerted a negative effect on adult filarial 
burdens at +12 weeks. Sex ratios were also not significantly distorted by drug treatment.
Median Wolbachia loads per female B. malayi were estimated at 2.57 × 107 (range 7.74 × 106–4.76 × 107) 
derived from untreated SCID mouse infections. Filarial Wolbachia loads from vehicle control treated mice lev-
els were also similar (median 3.35 × 107, range 6.51 × 106–9.33 × 107). Doxycycline reduced Wolbachia in both 
a dose and dose-duration dependent-manner (Fig. 3b). In line with clinical data from doxycycline-treated LF 
patients, and confirming bio-equivalent dose calibrations, doxycycline mediated significant (>90% threshold) 
depletion of Wolbachia in 28 days, dependent on dose (median reduction 90.35%, 25 mg/Kg bid x 28d). In com-
parison, minocycline mediated improved efficacy with reduced dosages and/or dose-durations. A 25 mg/Kg 
qd minocycline regimen yielded significant, yet sub-optimal, reductions in Wolbachia following 28 day dosing, 
which was an improvement compared with matching doxycycline dose delivered for 42 days (median reduction 
85.08%, minocycline x 28d vs 66.30%, doxycycline x 42d, P = 0.0307, Mann-Whitney test). Increasing the dose 
of minocycline to 25 mg/Kg bid mediated a significant, above clinical threshold effect in depletion of >90% of 
Figure 3. (a): Schematic of Brugia malayi (Bm) SCID mouse PD model with oral dosing regimens (MK: mg/
Kg). (b): Effect on Wolbachia depletion following indicated human bioequivalent dosing of doxycycline (DOX) 
or minocycline (MIN). Data plotted is Wolbachia surface protein (wsp) single gene copy number per adult female 
worm, horizontal bars are median levels. Shaded area indicates levels above 90% depletion compared with 
median vehicle control level (dashed line). Data is derived from between 10 and 40 adult female worms pooled 
from groups of between 4–12 mice per drug treatment. Significant differences between the 13 treatment groups 
were identified by Kruskal-Wallis, two-tailed 1-way ANOVA, alpha = 0.05, P < 0.0001 with Dunn’s multiple 
tests post-hoc comparing drug groups vs vehicle control, indicated *P < 0.05, **P < 0.01 and ***P < 0.001. (c): 
Effect on microfilariae (mf) production following human bioequivalent dosing of doxycycline or minocycline. 
Data is total mf enumerated from the infection site in groups of 4 to 12 mice per drug group. Horizontal bars are 
median levels. Significant differences between the 13 treatment groups were identified by Kruskal-Wallis, two-
tailed 1-way ANOVA, alpha = 0.05, P < 0.0001 with Dunn’s multiple tests post-hoc comparing drug groups vs 
vehicle control, indicated *P < 0.05, **P < 0.01 and ***P < 0.001.
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5Scientific RepoRts | 6:23458 | DOI: 10.1038/srep23458
Wolbachia following 28 day dosing, an improvement on matching doxycycline dose (median reduction 99.51%, 
minocycline vs 90.35%, doxycycline, P < 0.0001, Mann-Whitney test).
Depleting Wolbachia from filarial nematodes blocks embryogenesis34 and results in a waning of circulating 
LF mf in the blood or O. volvulus mf in the skin, which can be detected 2–4 months after start of effective doxy-
cycline treatment14,18,22. Therefore, comparative effects of doxycycline and minocycline in blockading B. malayi 
embryogenesis were assessed in vivo by measuring accumulations of released mf at the peritoneal infection site 
(Fig. 3c). At 12 weeks post-infection, 89% of all vehicle treated mice contained mf (median 5396, range 0–23008). 
Doxycycline mediated a significant reduction in peritoneal mf loads following 28 or 42 days 25 mg/Kg qd doses 
and bid dosing of 25 mg/Kg for 28 days (Fig. 3c). However, at all doses and durations tested, at the evaluation 
endpoint blockade of embryogenesis was incomplete with between 20–50% of treated animals harbouring motile 
mf (Fig. 3c). In comparison, minocycline mediated significant reduction in peritoneal mf loads at all durations 
and doses tested, as little as 7 days at 25 mg/Kg qd, and rendered a complete blockade of embryogenesis after 3–4 
weeks of exposure to 25 mg/Kg qd or bid regimens.
Immediate anti-Wolbachia pharmacological effect of escalating minocycline dose regimens. 
To assess the immediate pharmacological effect of minocycline dose regimens (i.e. without the impact of a wash-
out period, post antibiotic effect) adult B. malayi parasitized mice were dosed with oral minocycline at 25, 40 or 
80 mg/Kg bid for 7 days or 25 mg/Kg bid for 14 or 28 days (Fig. 4a). Adult worms were recovered immediately 
following the last dose and Wolbachia loads in female adult nematode tissue was enumerated (Fig. 4b). Seven day 
dosing of 25, 40 or 80 mg/Kg bid lead to sub-threshold, yet significant, depletions of Wolbachia (71.65–84.08% 
median depletions, 25–80 mg/Kg bid, Kruskal-Wallis 1-way ANOVA P < 0.0001). There were no significant 
changes in the level of Wolbachia depletion when comparing dose escalations between 25–80 mg/Kg bid over a 
7-day course by 1-way ANOVA. When comparing extended dose durations, both 2 week and 4 week exposures 
led to >90% Wolbachia depletions (94.93% and 98.17%, respectively).
Pharmacokinetic-Pharmacokinetic modelling. PKPD modelling incorporating an effect compartment 
was employed to assess the rate of Wolbachia reduction. The anti-Wolbachia potencies at the effect site were set 
equal to potencies determined in previously validated assay using Wolbachia infected cells and transfer coef-
ficients to the effect site were fitted using non-parametric non-linear mixed effects modelling. Table 4 shows 
in vitro potencies and fitted transfer coefficients for both tetracyclines. The combination of minocycline’s 
increased potency and faster transfer to the effect compartment leads to 1.7-fold greater anti-Wolbachia effect in 
comparison to doxycycline with the transfer rate into the effect site being 24-fold higher for minocycline.
Discussions
The A∙WOL consortium aims to reduce the treatment time of anti-Wolbachia macrofilaricidal chemotherapies to 
improve test-and-treat drug regimen delivery, adherence and to reduce costs of treatment. Minocycline has been 
shown to have a similar anti-Wolbachia effect to doxycycline in vitro with improved in vivo efficacy, making it an 
ideal candidate for further PKPD investigation28.
Traditionally pre-clinical and clinical studies of anti-filarial chemotherapies have linked drug dosage to phar-
macological effect35–37. Linking dosage to pharmacological effect when comparing chemotherapies is inherently 
flawed as the pharmacokinetics (absorption, distribution, metabolism and excretion) of different chemotherapies 
Treatment none
Vehicle 
(Water) Doxycycline Minocycline
Dose – – 25MKqd 25MKqd 25MKqd 25MKqd 25MKbid 25MKqd 25MKqd 25MKqd + 14d 25MKqd 25MKqd + 28d 25MKbid + 28d
duration – +28/42d +7d +14d +21d +28d +28d +42d +7d +21d
SCID n 7 22 5 4 4 5 5 9 5 5 5 13 5
Adult B. malayi
min 1 0 14 7 11 6 1 1 0 1 8 0 0
Median^ 3 6 21** 9 15 9 6 6 19 10 12 6 6
max 5 19 22 11 19 13 10 21 23 21 20 15 10
total 22 122 96 36 60 49 28 69 76 55 70 81 49
Female B. malayi (% total)
min 20.0 0 35.7 20.0 43.8 44.4 45 36.4 0 1 8 0 0
Median| 70.8 59.2 52.9 59.8 46.4 50.0 83 61.8 50 60.0 54.6 66.7 70.7
max 100 100 63.6 72.7 57.1 63.0 100 100 62 100 63.2 100 100
Female B. 
malayi n 13 68 51 19 29 25 17 40 38 30 38 53 32
Wolbachia 
sample n 13 40 10 10 10 10 10 21 10 10 10 35 21
Table 3.  Parasitological output from comparative in vivo efficacy of clinically bioequivalent doxycycline 
and minocycline regimens against adult stage Brugia malayi Wolbachia. ^Kruskal Wallis 1way ANOVA 
P = 0.003, DOX 25MKqd + 7d > Vehicle. **P < 0.01, all other regimens ns. |Kruskal Wallis 1way ANOVA ns.
www.nature.com/scientificreports/
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within a target population can vary radically and therefore the systemic exposure of the drug at the effect site can 
be significantly different for the same dose of two different drugs. This is an even greater problem in preclinical 
models where species and strain differences in PK can be radically different. The resultant pharmacological effect 
can therefore deviate for drugs with similar in vitro potencies. The use of rational drug development employing 
PKPD modelling or model-based drug development (MBDD) is a paradigm that has been used extremely effec-
tively with preclinical and clinical development in other disease areas38–40. We propose, supported by the data 
presented here, that the NTD community, particularly those involved in the development of new chemotherapies, 
need to embrace these strategies if we are ever to optimise global treatment and elimination programmes to meet 
control and elimination targets.
In this work, for the first time, we use PKPD modelling to rationally develop an anti-filarial chemotherapy by 
linking drug exposure to pharmacological effect. Specifically, we use PKPD analysis to evaluate the relative effi-
cacy of minocycline to the gold standard anti-Wolbachia macrofilaricide doxycycline in our Brugia malayi murine 
Figure 4. (a): Schematic of Brugia malayi (Bm) SCID mouse PD model with oral dosing regimens (MK: mg/Kg, 
ip: intraperitoneal route). (b): Effect on Wolbachia depletion following indicated minocycline (MIN). Data 
plotted is Wolbachia surface protein (wsp) single gene copy number per adult female worm, horizontal bars are 
median levels. Median vehicle control level is indicated by dashed line. Data is from 10–15 adult female worms 
pooled from between 5–10 mice per drug treatment. Significant differences between 7 day MIN dose escalation 
groups and vehicle were compared by Kruskal-Wallis, two-tailed 1-way ANOVA, alpha = 0.05, P < 0.0001 
with Dunn’s multiple tests post-hoc comparing all groups indicated *P < 0.05, **P < 0.01 and ***P < 0.001. 
Significant differences between MIN 25MKbid for 14 or 28d vs corresponding length of vehicle were compared 
by Mann-Whitney tests, two-tailed, alpha = 0.05, P < 0.0001 indicated***.
Effect site 
EC50 (nM) K12/K21
Ratio of AUCPD 
curve ( 0→28d)
Doxycycline 15.32 4.36 × 10−7/8.06 × 10−4 1
Minocycline 11.75 1.08 × 10−5/1.49 × 10−3 1.7
Table 4.  PKPD modelling parameters for doxycycline and minocycline. Area under the PD curve for a 28 
day 25 mg/Kg bid dosing regimen is also shown.
www.nature.com/scientificreports/
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infection model of lymphatic filariasis. There is an inherent disconnect between the human pharmacokinetics 
and murine pharmacokinetics of tetracyclines with murine body weight normalised clearances being far greater 
than is the case in their human counterparts30,31,41. To address this disconnect we determined the murine pharma-
cokinetics of these tetracyclines, minocycline was found to have inferior pharmacokinetics to doxycycline, giving 
approximately 3-fold less exposure in comparison to doxycycline in our murine models. Monte-Carlo simulations 
of murine and human exposures were used to establish that a bi-daily 25 mg/Kg murine dose gave an approximately 
bioequivalent exposure to the currently recommended 100–200 mg daily clinical dose of the tetracycline. At bioe-
quivalent exposures minocycline was found to deplete Wolbachia levels by >99% after a 28 day treatment regimen 
in the Brugia malayi murine model. This Wolbachia reduction is far greater than the 1 log-unit drop associated with 
irreversible sterilisation filarial tissues in clinical studies, the target clinical PD endpoint14,33. In contrast doxycycline 
at a 25 mg/Kg bid bioequivalent dosing regimen achieved a 90.35% reduction within the same 28 day time frame.
PKPD modelling was used to quantify that minocycline is 1.7-fold more effective than doxycycline when 
administered at the 25 mg/Kg bid bioequivalent dosage regimen, despite a 3-fold lower exposure than doxycycline 
and having a similar potency at the effect site as modelled by in vitro potencies. A PKPD model incorporating an 
effect compartment was employed; this enabled us to further dissect the origins of the superior efficacy of min-
ocycline given its inferior systemic exposure and similar potency to doxycycline. These properties don’t account 
for the increase in efficacy indicating there are other factors influencing its in vivo efficacy. The transfer rates to 
and from the effect site were determined from the PKPD analysis, the transfer rate constant to the effect site was 
predicted to be 24-fold higher for minocycline in comparison to doxycycline whereas the efflux from the effect 
site was predicted to only marginal faster for minocycline. The difference in transfer rates in to the effect site could 
be due to increase bioavailability at the effect site from the systemic exposure or the transfer coefficient could be 
a lumped parameter masking the production of an active metabolite of minocycline that has a far greater potency 
than doxycycline. We have sought to explain the difference in transfer rate to the effect site through analysis of 
the physicochemical properties of doxycycline and minocycline focusing on physicochemical properties synony-
mous with permeability42,43, namely calculated octanol-water partition coefficient (ALogP), number of hydrogen 
bond acceptors/donors (H-Acceptor/H-Donor), molecular mass (MW), number of rotatable bonds (RotB) and 
molecular polar surface area (PSA). Figure 5 shows a radar plot of the physicochemical properties of doxycycline 
and minocycline, it can be seen that as expected the physicochemical properties of doxycycline and minocycline 
are similar, however there are notable differences. The optimal region for physicochemical properties with respect 
to permeability and oral bioavailability as defined by previous analyses of experimental in vitro and in vivo data42–
44 are shown as shaded areas in Fig. 5. The physicochemical parameters of minocycline confer with more optimal 
regions of physicochemical space than doxycycline, in particular calculated LogP and number of hydrogen bond 
donors were sub-optimal for doxycycline in comparison to minocycline, furthermore minocycline’s molecular 
polar surface area (PSA) is more in-line with the recommend 140 Å2 cut-off limit for permeable compounds. 
These subtle differences may lead to a change in the transfer rates into the effect site.
The overall conclusion of this study is that minocycline is predicted to be superior to doxycycline as 
an anti-Wolbachia dependent macrofilaricide. The data suggest that not only can minocycline be used as an 
Figure 5. (a). Physicochemical properties of doxycycline and minocycline shaded regions represents those 
synonymous with favourable permeation. (b). Chemical structures of doxycycline and minocycline.
www.nature.com/scientificreports/
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alternative to doxycycline in test and treat strategies it may offer some advantages through either improved 
Wolbachia kill rates or lower dosage requirements, which may impact on tolerability or safety profiles. Although 
the incidence of AEs with either drug is very low there is a slightly higher incidence of AE with minocycline45. The 
shorter treatment period may offset this slight increase in risk of AE with minocycline. It will now be important 
to undertake clinical evaluations of minocycline, supported through full PK analysis, to confirm these benefits. 
Recently, a clinical trial has shown a single dose triple combination of diethylcarbamazine, albendazole, and iver-
mectin has shown microfilaremia suppression in Bancroftian Filariasis for up to a year or more. These results are 
clearly promising, with the potential to accelerate MDA endpoints in non-African settings, where co-endemicity 
with either Loa loa or Onchocerca volvulus do not present a risk of severe adverse events. Ultimately, a number 
of chemotherapeutic tools will be need to eliminate filariasis, including anti-Wolbachia agents for settings where 
standard anti-filarials are contraindicated or compromised by reduced efficacy46.
We used PKPD modelling to ensure that drug exposures for our dosing regimens in our Brugia malayi preclini-
cal murine model are indicative of those of recommended clinical doses, given the Wobachia reduction achieved at 
bioequivalent doses of minocycline. We recommend that further clinical studies investigating the anti-Wolbachia 
effect of 2–4 weeks of 100 or 200 mg/day minocycline in patient population with lymphatic filariasis and onchocer-
ciasis. Furthermore, treatment time maybe further truncated by combination with other classes of anti-Wolbachia 
registered drugs or in combination with current anti-filarial drugs, which are actively being pursued by A∙WOL.
Methods
Parasites. The parasite life cycle of B. malayi (Bm) filarial nematode (TRS strain)47 was maintained in mos-
quitoes and susceptible Meriones unguiculatus gerbils at LSTM. Infective Bm larvae (BmL3) were generated using 
protocols as previously described29. Briefly, female adult Aedes aegypti mosquitoes were fed with microfilariae 
collected from infected gerbils by catheterisation, as described previously48. Microfilariae were mixed with human 
blood and fed to mosquitoes using an artificial membrane feeder (Hemotek® ). BmL3 stage larvae were propa-
gated by rearing the blood-fed mosquitoes for 14 days. BmL3 larvae were then harvested from infected mosqui-
toes by crushing. Purification of the inoculum was performed using previously optimised protocols25.
Animals. Male BALB/c SCID mice were procured from Harlan Laboratories, UK. All animals were housed 
at an approved animal housing facility under specific pathogen-free (SPF) conditions. Approval was obtained for 
all animal experiments from the ethical committees of the University of Liverpool and LSTM. Experiments were 
conducted according to Home Office (UK) requirements.
Parasite Infections. 100 freshly collected, motile Brugia malayi L3 larvae were injected via the 
intra-peritoneal route into BALB/c SCID mice. Efficiencies of inoculations were confirmed by needle washout.
Preparation and administration of Drugs/Compounds. Infected mice were administered 100 μL of 
either doxycycline or minocycline solution via oral gavage six weeks after infection. Doxycycline was admin-
istered once or twice daily at 25 mg/Kg for 7, 14, 21, 28 or 42 days. Minocycline was administered in dosage 
regimens mirroring those for doxycycline. Additionally, minocycline was administered twice daily at 25, 40 and 
80 mg/Kg for 7 days. Both doxycycline and minocycline were dissolved in water and all reagents were purchased 
from Sigma unless otherwise stated.
Parasitological Readouts. Mice were necropsied 12 weeks after infection unless otherwise stated. A total 
of 5 individual screens were run, each containing groups of between 4/5 SCID mice per treatment arm. Peritoneal 
washes using RPMI medium were employed to recover adults and microfilariae (mf). Adult worms were removed 
and stored overnight in fresh medium at 4 °C before being washed in cold PBS. Adult stages were subsequently 
counted and their gender determined. For subsequent qPCR analysis of Wolbachia loads, 10–15 female adults 
were utilised per treatment group, derived from each screen. Between 2–4 female worms were selected, randomly, 
from individual mice, to avoid bias due to intra-group dosing variation. Mf were pelleted from peritoneal wash-
ings by centrifugation (300 g, 5 minutes, 4 °C, low brake), re-suspended in 1–2 ml of medium and the total mf 
quantity contained within peritoneal lavage enumerated by microscopy.
Quantification of Wolbachia bacteria numbers using qPCR assay. Extraction of DNA from individual 
female worms was performed using a DNeasy Blood and Tissue Kit (Qiagen) according to manufacturer’s instruc-
tions. Quantification of Bm Wolbachia wsp copy numbers was performed using qPCR as previously described49.
Determination of in vitro potencies. The anti-Wolbachia potency of doxycycline and minocycline 
for use in the PKPD model was determined in vitro, utilising the routine A·WOL screening assay as described 
previously50. In brief the mosquito (Aedes albopictus) derived cell line (C6/36), stably infected with Wolbachia 
pipientis (wAlbB) (C6/36 (wAlbB)) was incubated with the relevant drugs in a concentration range in order 
to determine a dose response. The drugs were incubated for 7 days with 2,000 cells per well on a 384 well plate 
(CellCarrier-384 Ultra, PerkinElmer) in Leibovitz media (Life Technologies™ ) supplemented with 20% foetal 
bovine serum (FBS, Fisher Scientific), 2% tryptose phosphate broth (Sigma-Aldrich) and 1% non-essential amino 
acids (Sigma-Aldrich). The end-point read out utilised DNA staining of both the host cell nuclei and intracellular 
Wolbachia (SYTO® 11) combined with a high content imaging system (Operetta® , PerkinElmer) and analysed 
using the associated Harmony® software through a cytoplasm texture analysis.
Pharmacokinetic studies in BALB/c SCID mice. Rich pharmacokinetics studies were performed to 
characterise the pharmacokinetic profiles of orally administered doxycycline and minocycline in uninfected 
BALB/c SCID mice (weight 24–28 g). 25 mg/Kg of doxycycline or minocycline was administered via oral gavage 
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in the appropriate vehicles (PEG300/Propylene Glycol/H20 (55%,25%,20%)). Blood samples were collected via 
microsampling from the tail vein. For both drugs, serial blood samples were collected up to 8 hours after a single 
dose and on day 7 after once daily dosing.
Blood samples (20 μL) were collected via a pipette with a pre-heparinised tip and were immediately lysed with 
40 μL of ice cold ddH2O and subsequently frozen at − 80 oC until time of analysis. Sparse samples were obtained 
from the pharmacodynamic studies in the Brugia malayi BALB/c SCID murine infection model to ensure that 
drug exposures were in line with those observed in the rich pharmacokinetic studies.
Bioanalysis. Doxycycline and minocycline plasma drug concentrations were quantified using LCMS (liquid 
chromatography mass spectrometry) on a UHPLC (ultrahigh pressure liquid chromatography) system linked to 
a triple-quadruple TSQ Quantum Access mass spectrometer (Thermo Scientific, Hemel Hempstead, UK) with a 
heated-electrospray ionization (H-ESI) source. Chromatographic separation was performed using a gradient via 
a Hypersil C18 Gold column (100 × 2.1 mm, 1.9 μm particle size) reverse-phase column (Thermo Scientific, UK). 
All methods incorporated the use of appropriate internal standards and were validated using FDA guidelines 
which are internationally recognised51.
For both doxycycline and minocycline samples were prepared as follows: 20 μL of blood sample containing the 
drug was extracted with 120 μL acetonitrile/methanol (80%/20%) containing the internal standard (doxycycline 
and minocycline at a concentration of 1 μg/mL were employed as internal standards for each other). Samples were 
then filtered using 96 well filter plates (MultiScreen Solvinert, 0.45 μm hydrophobic PTFE filter plates, Millipore 
Ltd, Ireland) and the filtrates were transferred to clean glass autosampler vials for analysis. Samples were assayed 
alongside a whole blood calibration curve (range 0 - 50 μg/mL), with quality control samples at low 0.5 μg/mL, 
medium 15 μg/mL, and high 40 μg/mL concentrations for both doxycycline and minocycline. All standard curves 
were described using an equal weighted linear regression equation using data acquisition software LC Quan 
(Version 2.5.6.Thermo Scientific, Hemel Hempstead, UK). The correlation coefficient (r2) for both DOX and MN 
calibration curves exceeded 0.99. Lower limits of quantification for doxycycline and minocycline were 250 ng/mL 
and 300 ng/mL, respectively, with a signal-to-noise ratio of 5:1 and a coefficient of variation (CV) of less than 13% 
for both tetracyclines.
Pharmacokinetics-Pharmacodynamic Modelling. All pharmacokinetic and pharmacodynamics mod-
elling and simulation was performed using Pmetrics52 within R version 3.1.053 A one-compartment model with 
an absorptive compartment for oral dosing was used for modelling the pharmacokinetics of doxycycline and 
minocycline as described by the differential equations 1a and 1b:
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where X1 and X2 are the amounts of drug in the absorptive and central compartments, representing gut and sys-
temic circulation, respectively. The pharmacokinetic parameters ka, CL, V represent the absorption rate constant, 
clearance and volume of distribution, respectively.
The link between drug exposure and pharmacological effect was quantified using PK/PD modelling. The 
pharmacodynamics response for the anti-Wolbachia effect exerted by doxycycline and minocycline was defined 
to be number of Wolbachia in each worm normalised to the relevant vehicle treated control and expressed as a 
percentage reduction. An effect compartment, X3, was used to account for the delay in observed effect as has been 
previously recommended54–56 and as defined by the differential equations 2a and 2b:
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the parameters K12 and K21 in equations 2a and 2b represent transfer rate constants to and from the effect com-
partment. The pharmacodynamics response was modelled using an Emax model (equation 3) that depends on 
drug concentration in the effect compartment.
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where EC50, Emax, and Vf represent the maximum effect, the concentration to achieve 50% of the maximal effect 
and the effect site volume of distribution. The relative EC50 at the effect site was fixed to the in vitro EC50 deter-
mined in Wolbachia infected A. albopictus cells, Emax 99.999% and Vf is assumed to be proportional to the volume 
of distribution of the central compartment. The transfer rate constants, K12 and K21 to and from the effect com-
partment were fitted for each tetracycline.
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Model fitting was performed via protocol used previously established protocols57,58 Briefly, linear regression 
(intercept close to 0, slope close to 1) was used to assess the goodness-of-fit of the observed/predicted values, the 
coefficient of determination of the linear regression and log-likelihood values. A statistically significant improve-
ment in the log-likelihood value (P, 0.05) was required for a more complex model to be supported.
Statistical tests. Continuous variables (wsp copy number/female B. malayi worm and total peritoneal 
mf/SCID mouse) were pooled per treatment group from independent screens. Statistical significance of dif-
ferences between independent groups was assessed using two-tailed non-parametric statistical hypothesis. 
The Mann-Whitney U test was employed when comparing two groups whereas the Kruskal-Wallis test fol-
lowed by Dunn’s multiple comparisons test, post-hoc, was used in the case of comparing more than two groups. 
Significance level was set to alpha = 0.05.
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